These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11943448)

  • 1. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.
    Emery S; Abrams DI; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD;
    Control Clin Trials; 2002 Apr; 23(2):198-220. PubMed ID: 11943448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants.
    Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G;
    HIV Clin Trials; 2006; 7(2):70-85. PubMed ID: 16798622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 therapy in patients with HIV infection.
    ; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
    N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why patients continue to participate in clinical research.
    Wendler D; Krohmal B; Emanuel EJ; Grady C;
    Arch Intern Med; 2008 Jun; 168(12):1294-9. PubMed ID: 18574086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
    J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
    Initio Co-ordinating Committee
    Control Clin Trials; 2001 Apr; 22(2):160-75. PubMed ID: 11306154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
    Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
    AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in antiretroviral therapy.
    Wilkin TJ; Taylor B; Olender S; Hammer SM
    Top HIV Med; 2009; 17(2):68-88. PubMed ID: 19401609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era.
    Mocroft A; Neaton J; Bebchuk J; Staszewski S; Antunes F; Knysz B; Law M; Phillips AN; Lundgren JD; ;
    Clin Trials; 2006; 3(2):119-32. PubMed ID: 16773954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
    Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
    HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.
    Thiébaut R; Jarne A; Routy JP; Sereti I; Fischl M; Ive P; Speck RF; D'Offizi G; Casari S; Commenges D; Foulkes S; Natarajan V; Croughs T; Delfraissy JF; Tambussi G; Levy Y; Lederman MM
    Clin Infect Dis; 2016 May; 62(9):1178-1185. PubMed ID: 26908786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
    Regnault A; Marfatia S; Louie M; Mear I; Meunier J; Viala-Danten M
    Clin Trials; 2009 Dec; 6(6):574-84. PubMed ID: 19933717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 for the treatment of HIV infection.
    Simmons P
    Res Initiat Treat Action; 1999 Apr; 5(2):17-21. PubMed ID: 11366280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 for the treatment of human immunodeficiency virus infection.
    Temesgen Z
    Drugs Today (Barc); 2006 Dec; 42(12):791-801. PubMed ID: 17285152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 studies.
    Treat Rev; 1995 May; (no 18):7. PubMed ID: 11362595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design issues in initial HIV-treatment trials: focus on ACTG A5095.
    Ribaudo HJ; Kuritzkes DR; Schackman BR; Acosta EP; Shikuma CM; Gulick RM
    Antivir Ther; 2006; 11(6):751-60. PubMed ID: 17310819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.